These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34851258)

  • 1. [Vaccination against herpes zoster].
    Larsen CS; Helleberg M
    Ugeskr Laeger; 2021 Nov; 183(47):. PubMed ID: 34851258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
    Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
    Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
    Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
    van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
    BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination for quality of life: herpes-zoster vaccines.
    Lang PO; Aspinall R
    Aging Clin Exp Res; 2021 Apr; 33(4):1113-1122. PubMed ID: 31643072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
    Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
    Giannelos N; Ng C; Curran D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials.
    Kim JH; Diaz-Decaro J; Jiang N; Hwang SJ; Choo EJ; Co M; Hastie A; Hui DSC; Irimajiri J; Lee J; Leung EM; Tang H; Tsuru T; Watson P; Wu Z; Yu CJ; Yuan Y; Zahaf T; Cunningham AL; Schuind A
    Hum Vaccin Immunother; 2021 Jul; 17(7):2050-2057. PubMed ID: 33606577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials.
    Willer DO; Oostvogels L; Cunningham AL; Gervais P; Gorfinkel I; Hyung Kim J; Talarico C; Wascotte V; Zahaf T; Colindres R; Schuind A;
    Vaccine; 2019 Oct; 37(43):6262-6267. PubMed ID: 31537443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
    Oh H; Tan C; Williams C; Giannelos N; Ng C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant Zoster Vaccine (Shingrix
    Syed YY
    Drugs Aging; 2018 Dec; 35(12):1031-1040. PubMed ID: 30370455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
    J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes Zoster Vaccines.
    Harbecke R; Cohen JI; Oxman MN
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes zoster: treatment, management, and prevention with the recombinant DNA vaccine.
    Li E; Closmann JJ; Jordan RC
    Gen Dent; 2024; 72(1):54-57. PubMed ID: 38117642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination against herpes zoster in developed countries: state of the evidence.
    Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M
    Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes zoster in Belgium: a new solution to an old problem.
    Nikkels AF; Schoevaerdts D; Kauffmann F; Strubbe F; Bensemmane S
    Acta Clin Belg; 2024 Jun; 79(3):205-216. PubMed ID: 38781037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
    Johnson RW
    Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.